Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotalol Hydrochloride

FDA-approved product (tablet, oral), marketed as Betapace, Betapace Af, Sorine and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sotalol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta blocking agents, non-selective
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotalol Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotalol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

    NCT07405671 · start 2026-09

    Registered record
    Registry ID
    NCT07405671
    Conditions
    Atrial Fibrillation (AF); Coronary Artery Disease
    Interventions
    flecainide; Sotalol or Amiodarone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2029-12
    Enrolment
    988

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF); Coronary Artery Disease
    Interventionflecainide; Sotalol or Amiodarone
    PhasePhase 4
    Registry statusRecruiting

  • Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes

    NCT07445334 · start 2026-03-01

    Registered record
    Registry ID
    NCT07445334
    Conditions
    Premature Ventricular Complexes; Premature Ventricular Contraction (PVC); Premature Ventricular Beats
    Interventions
    Catheter ablation; Medical therapy: Anti-arrhythmic drugs (AAD) and/or beta-adrenergic blocking agents (BB)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2028-03-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ventricular Complexes; Premature Ventricular Contraction (PVC); Premature Ventricular Beats
    InterventionCatheter ablation; Medical therapy: Anti-arrhythmic drugs (AAD) and/or beta-adrenergic blocking agents (BB)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Efficacy of Early Rhythm Control in AF With TR Patients

    NCT07607093 · start 2026-02-18

    Registered record
    Registry ID
    NCT07607093
    Conditions
    Atrial Fibrillation (AF); Tricuspid Regurgitation (TR)
    Interventions
    Anti-arrhythmic drugs for rhythm control; DC cardioversion, catheter ablation for rhythm control; Usual care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-02-18
    Completion
    2027-02-28
    Enrolment
    5,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF); Tricuspid Regurgitation (TR)
    InterventionAnti-arrhythmic drugs for rhythm control; DC cardioversion, catheter ablation for rhythm control; Usual care
    PhaseNot recorded
    Registry statusRecruiting

  • Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

    NCT06783868 · start 2025-10

    Registered record
    Registry ID
    NCT06783868
    Conditions
    Atrial Fibrillation; Stroke
    Interventions
    Catheter Ablation; Market-approved AVNB, OAC and AAD
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2027-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Stroke
    InterventionCatheter Ablation; Market-approved AVNB, OAC and AAD
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation

    NCT06322017 · start 2024-04-09

    Registered record
    Registry ID
    NCT06322017
    Conditions
    Atrial Fibrillation
    Interventions
    Rhythm control by Pulmonary Vein Isolation (PVI) procedure; Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-09
    Completion
    2030-04-09
    Enrolment
    294

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRhythm control by Pulmonary Vein Isolation (PVI) procedure; Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)
    PhaseNot applicable
    Registry statusRecruiting

  • Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

    NCT06096337 · start 2023-12-28

    Registered record
    Registry ID
    NCT06096337
    Conditions
    Persistent Atrial Fibrillation
    Interventions
    FARAPULSE™ Pulsed Field Ablation (PFA) System; Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-12-28
    Completion
    2028-02-04
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Atrial Fibrillation
    InterventionFARAPULSE™ Pulsed Field Ablation (PFA) System; Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
    PhaseNot applicable
    Registry statusActive not recruiting

  • First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

    NCT05939076 · start 2023-08-21

    Registered record
    Registry ID
    NCT05939076
    Conditions
    Atrial Fibrillation, Persistent
    Interventions
    Pulmonary vein isolation; dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2023-08-21
    Completion
    2028-12
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation, Persistent
    InterventionPulmonary vein isolation; dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
    PhasePhase 3
    Registry statusNot yet recruiting

  • EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment

    NCT05790707 · start 2023-04-21

    Registered record
    Registry ID
    NCT05790707
    Conditions
    Mild Cognitive Impairment; Persistent Atrial Fibrillation
    Interventions
    Atrial fibrillation ablation + antiarrhythmic drugs; Antiarrhythmic drug
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-04-21
    Completion
    2027-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Persistent Atrial Fibrillation
    InterventionAtrial fibrillation ablation + antiarrhythmic drugs; Antiarrhythmic drug
    PhaseNot applicable
    Registry statusRecruiting

  • CAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories

    NCT05364866 · start 2022-05-01

    Registered record
    Registry ID
    NCT05364866
    Conditions
    Cardiovascular Diseases
    Interventions
    Antiarrhythmic drug Therapy; cryoballoon ablation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-05-01
    Completion
    2024-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionAntiarrhythmic drug Therapy; cryoballoon ablation
    PhaseNot recorded
    Registry statusUnknown

  • Prospective Evaluation Analysis and Kinetics Registry

    NCT05247320 · start 2022-02-04

    Registered record
    Registry ID
    NCT05247320
    Conditions
    Atrial Arrhythmia
    Interventions
    Sotalol Injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-02-04
    Completion
    2023-08-30
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Arrhythmia
    InterventionSotalol Injection
    PhaseNot recorded
    Registry statusCompleted

  • Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

    NCT04942834 · start 2021-10-01

    Registered record
    Registry ID
    NCT04942834
    Conditions
    Atrial Fibrillation, Persistent; Arrhythmias, Cardiac
    Interventions
    Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone; cryoballoon ablation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-10-01
    Completion
    2025-08-23
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation, Persistent; Arrhythmias, Cardiac
    InterventionAntiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone; cryoballoon ablation
    PhaseNot applicable
    Registry statusCompleted

  • Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation

    NCT05279833 · start 2021-09-24

    Registered record
    Registry ID
    NCT05279833
    Conditions
    Atrial Fibrillation
    Interventions
    dronedarone; sotalol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-24
    Completion
    2022-03-31
    Enrolment
    87,810

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventiondronedarone; sotalol
    PhaseNot recorded
    Registry statusCompleted

  • Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

    NCT04757584 · start 2021-04-01

    Registered record
    Registry ID
    NCT04757584
    Conditions
    Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Disease
    Interventions
    Beta blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2023-04-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure +1 more
    InterventionBeta blockers
    PhasePhase 4
    Registry statusCompleted

  • Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

    NCT02347111 · start 2020-12-31

    Registered record
    Registry ID
    NCT02347111
    Conditions
    Atrial Fibrillation
    Interventions
    Flecainide; Sotalol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-12-31
    Completion
    2026-06-30
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionFlecainide; Sotalol
    PhasePhase 4
    Registry statusRecruiting

  • Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

    NCT05524077 · start 2020-07-08

    Registered record
    Registry ID
    NCT05524077
    Conditions
    Heart Disease Structural Disorder; Ventricular Tachycardia; Cardiomyopathy, Dilated; Sarcoidosis; Cardiomyopathy, Hypertrophic; Cardiomyopathy Ischemic; Cardiomyopathy, Familial; Arrhythmogenic Right Ventricular Cardiomyopathy 1; Arrhythmogenic Left Ventricular Cardiomyopathy
    Interventions
    Ablation; Anti-arrhythmic Drugs (AADs)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2020-07-08
    Completion
    2026-06-30
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Disease Structural Disorder; Ventricular Tachycardia; Cardiomyopathy, Dilated; Sarcoidosis +5 more
    InterventionAblation; Anti-arrhythmic Drugs (AADs)
    PhaseNot applicable
    Registry statusActive not recruiting